• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Gemogenovatucel-T（Vigil）在复发性卵巢癌中的长期随访：生存情况及免疫反应的分子信号

Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer.

作者信息

Rocconi Rodney P, Stanbery Laura, Madeira da Silva Luciana, Barrington Robert A, Aaron Phylicia, Manning Luisa, Horvath Staci, Wallraven Gladice, Bognar Ernest, Walter Adam, Nemunaitis John

机构信息

Mitchell Cancer Institute, Division of Gynecologic Oncology, University of South Alabama, Mobile, AL 36604, USA.

Gradalis, Inc., 2545 Golden Bear Drive, Suite 110, Carrollton, TX 75006, USA.

出版信息

Vaccines (Basel). 2021 Aug 12;9(8):894. doi: 10.3390/vaccines9080894.

DOI:10.3390/vaccines9080894
PMID:34452019
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8402348/
Abstract

AIM

To determine the relationship between gene expression profile (GEP) and overall survival (OS) by NanoString following treatment with Vigil.

PATIENTS AND METHODS

Recurrent ovarian cancer patients ( = 21) enrolled in prior clinical trials.

RESULTS

GEP stratified by TIS vs. TIS demonstrated OS benefit (NR vs. 5.8 months HR 0.23; = 0.0379), and in particular, MHC-II elevated baseline expression was correlated with OS advantage ( = 0.038). Moreover, 1-year OS was 75% in TIS patients vs. 25% in TIS ( = 0.03795). OS was also correlated with positive γ-IFN ELISPOT response, 36.8 vs. 23.0 months (HR 0.19, = 0.0098).

CONCLUSION

Vigil demonstrates OS benefit in correlation with TIS score, elevated MHC-II expression and positive γ-IFN ELISPOT in recurrent ovarian cancer patients.

摘要

目的

通过NanoString技术确定使用Vigil治疗后基因表达谱（GEP）与总生存期（OS）之间的关系。

患者与方法

纳入先前临床试验中的复发性卵巢癌患者（n = 21）。

结果

TIS与TIS分层的GEP显示出OS获益（未达到与5.8个月相比，风险比[HR]为0.23；P = 0.0379），特别是，MHC-II基线表达升高与OS优势相关（P = 0.038）。此外，TIS患者的1年OS率为75%，而TIS患者为25%（P = 0.03795）。OS也与γ-干扰素酶联免疫斑点试验（ELISPOT）阳性反应相关，分别为36.8个月和23.0个月（HR 0.19，P = 0.0098）。

结论

Vigil在复发性卵巢癌患者中显示出与TIS评分、MHC-II表达升高及γ-干扰素ELISPOT阳性相关的OS获益。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a418/8402348/a03de7d9f4d0/vaccines-09-00894-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a418/8402348/da628b917bdc/vaccines-09-00894-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a418/8402348/5494586fe99f/vaccines-09-00894-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a418/8402348/49370700e406/vaccines-09-00894-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a418/8402348/3a144e7d1f42/vaccines-09-00894-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a418/8402348/27060df98644/vaccines-09-00894-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a418/8402348/8f448737af2e/vaccines-09-00894-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a418/8402348/a03de7d9f4d0/vaccines-09-00894-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a418/8402348/da628b917bdc/vaccines-09-00894-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a418/8402348/5494586fe99f/vaccines-09-00894-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a418/8402348/49370700e406/vaccines-09-00894-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a418/8402348/3a144e7d1f42/vaccines-09-00894-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a418/8402348/27060df98644/vaccines-09-00894-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a418/8402348/8f448737af2e/vaccines-09-00894-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a418/8402348/a03de7d9f4d0/vaccines-09-00894-g007.jpg

相似文献

1
Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer.Gemogenovatucel-T（Vigil）在复发性卵巢癌中的长期随访：生存情况及免疫反应的分子信号
Vaccines (Basel). 2021 Aug 12;9(8):894. doi: 10.3390/vaccines9080894.
2
Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer.Gemogenovatucel-T（Vigil）维持免疫治疗：同源重组修复功能（HRP）阳性卵巢癌的 3 年生存获益。
Gynecol Oncol. 2021 Dec;163(3):459-464. doi: 10.1016/j.ygyno.2021.10.004. Epub 2021 Oct 23.
3
Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.基因座蛋白聚糖-T（ Vigil ）免疫疗法在同源重组修复（ HRP ）有效的卵巢癌中显示出临床获益。
Gynecol Oncol. 2021 Jun;161(3):676-680. doi: 10.1016/j.ygyno.2021.03.009. Epub 2021 Mar 11.
4
Efficacy and safety of Gemogenovatucel-T (Vigil) immunotherapy for advanced ovarian carcinoma: A systematic review and meta-analysis of randomized controlled trials.Gemogenovatucel-T（Vigil）免疫疗法治疗晚期卵巢癌的疗效和安全性：一项随机对照试验的系统评价和荟萃分析
Front Oncol. 2022 Oct 21;12:945867. doi: 10.3389/fonc.2022.945867. eCollection 2022.
5
ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer.ENTPD1/CD39作为新诊断卵巢癌吉莫基因ovatucel-T维持治疗反应的预测标志物。
Commun Med (Lond). 2022 Aug 29;2:106. doi: 10.1038/s43856-022-00163-y. eCollection 2022.
6
Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer.Gemogenovatucel-T（Vigil）与度伐利尤单抗联合治疗复发的BRCA野生型三阴性乳腺癌或卵巢癌女性的初步研究。
Clin Med Insights Oncol. 2022 Aug 6;16:11795549221110501. doi: 10.1177/11795549221110501. eCollection 2022.
7
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.注射用维迪西妥单抗（VEGF）联合化疗一线治疗晚期胃癌的随机、双盲、安慰剂对照、多中心的 III 期临床研究（RCG108）
Lancet Oncol. 2020 Dec;21(12):1661-1672. doi: 10.1016/S1470-2045(20)30533-7.
8
Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy.杰莫尼莫他特（唯择）：基于 bi-shRNA 质粒的靶向免疫治疗。
Future Oncol. 2024;20(29):2149-2164. doi: 10.1080/14796694.2024.2376518. Epub 2024 Aug 5.
9
Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer.Vigil® DNA工程免疫疗法作为晚期卵巢癌维持治疗的II期研究。
Gynecol Oncol. 2016 Dec;143(3):504-510. doi: 10.1016/j.ygyno.2016.09.018. Epub 2016 Sep 24.
10
Three-year Follow up of GMCSF/bi-shRNA(furin) DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma.GMCSF/双短发夹RNA（弗林蛋白酶）DNA转染自体肿瘤免疫疗法（Vigil）治疗转移性晚期尤因肉瘤的三年随访
Mol Ther. 2016 Aug;24(8):1478-83. doi: 10.1038/mt.2016.86. Epub 2016 Apr 25.

引用本文的文献

1
Exome sequencing shows same pattern of clonal tumor mutational burden, intratumor heterogenicity and clonal neoantigen between autologous tumor and Vigil product.外显子组测序显示，自体肿瘤与Vigil产品之间的克隆性肿瘤突变负荷、肿瘤内异质性和克隆性新抗原具有相同模式。
Sci Rep. 2025 Mar 13;15(1):8637. doi: 10.1038/s41598-025-90136-7.
2
Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy.杰莫尼莫他特（唯择）：基于 bi-shRNA 质粒的靶向免疫治疗。
Future Oncol. 2024;20(29):2149-2164. doi: 10.1080/14796694.2024.2376518. Epub 2024 Aug 5.
3
3D engineered scaffold for large-scale Vigil immunotherapy production.

本文引用的文献

1
Mutation Status Impact on Autophagy and Immune Response: Unheralded Target.突变状态对自噬和免疫反应的影响：未被关注的靶点。
JNCI Cancer Spectr. 2020 Aug 24;4(6):pkaa077. doi: 10.1093/jncics/pkaa077. eCollection 2020 Dec.
2
Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance.关于晚期卵巢癌患者一线维持治疗中使用Vigil®进行2A期试验结果的长期随访
Gynecol Oncol Rep. 2020 Sep 17;34:100648. doi: 10.1016/j.gore.2020.100648. eCollection 2020 Nov.
3
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.
用于大规模 Vigil 免疫疗法生产的 3D 工程支架。
Sci Rep. 2024 Jul 5;14(1):15556. doi: 10.1038/s41598-024-65993-3.
4
High Tumor-Infiltrating Lymphocyte Count Is Associated with Distinct Gene Expression Profile and Longer Patient Survival in Advanced Ovarian Cancer.肿瘤浸润淋巴细胞计数高与晚期卵巢癌独特的基因表达谱及患者较长生存期相关。
Int J Mol Sci. 2023 Sep 5;24(18):13684. doi: 10.3390/ijms241813684.
5
Senescent cancer cell vaccines induce cytotoxic T cell responses targeting primary tumors and disseminated tumor cells.衰老癌细胞疫苗可诱导针对原发性肿瘤和播散性肿瘤细胞的细胞毒性 T 细胞反应。
J Immunother Cancer. 2023 Feb;11(2). doi: 10.1136/jitc-2022-005862.
6
TGF-beta signal transduction: biology, function and therapy for diseases.转化生长因子-β信号转导：生物学、功能及疾病治疗
Mol Biomed. 2022 Dec 19;3(1):45. doi: 10.1186/s43556-022-00109-9.
7
Efficacy and safety of Gemogenovatucel-T (Vigil) immunotherapy for advanced ovarian carcinoma: A systematic review and meta-analysis of randomized controlled trials.Gemogenovatucel-T（Vigil）免疫疗法治疗晚期卵巢癌的疗效和安全性：一项随机对照试验的系统评价和荟萃分析
Front Oncol. 2022 Oct 21;12:945867. doi: 10.3389/fonc.2022.945867. eCollection 2022.
8
ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer.ENTPD1/CD39作为新诊断卵巢癌吉莫基因ovatucel-T维持治疗反应的预测标志物。
Commun Med (Lond). 2022 Aug 29;2:106. doi: 10.1038/s43856-022-00163-y. eCollection 2022.
9
Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer.Gemogenovatucel-T（Vigil）与度伐利尤单抗联合治疗复发的BRCA野生型三阴性乳腺癌或卵巢癌女性的初步研究。
Clin Med Insights Oncol. 2022 Aug 6;16:11795549221110501. doi: 10.1177/11795549221110501. eCollection 2022.
10
Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6.病例报告：两名接受Vigil和FOLFOX-6治疗的结直肠癌肝转移患者具有显著的生存优势。
Vaccines (Basel). 2021 Oct 18;9(10):1201. doi: 10.3390/vaccines9101201.
注射用维迪西妥单抗（VEGF）联合化疗一线治疗晚期胃癌的随机、双盲、安慰剂对照、多中心的 III 期临床研究（RCG108）
Lancet Oncol. 2020 Dec;21(12):1661-1672. doi: 10.1016/S1470-2045(20)30533-7.
4
Resident Memory T Cells and Their Effect on Cancer.驻留记忆T细胞及其对癌症的影响。
Vaccines (Basel). 2020 Oct 1;8(4):562. doi: 10.3390/vaccines8040562.
5
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.尼拉帕利治疗新诊断的晚期卵巢癌患者。
N Engl J Med. 2019 Dec 19;381(25):2391-2402. doi: 10.1056/NEJMoa1910962. Epub 2019 Sep 28.
6
Chimeric Antigen Receptor T-Cell Therapy: Reach to Solid Tumor Experience.嵌合抗原受体 T 细胞疗法：在实体瘤中的探索。
Oncology. 2019;97(2):59-74. doi: 10.1159/000500488. Epub 2019 Jul 1.
7
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.帕博利珠单抗治疗晚期复发性卵巢癌患者的抗肿瘤活性和安全性：来自 II 期 KEYNOTE-100 研究的结果。
Ann Oncol. 2019 Jul 1;30(7):1080-1087. doi: 10.1093/annonc/mdz135.
8
An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer.嵌合抗原受体 (CAR) T 细胞免疫疗法治疗人类癌症简介。
Am J Hematol. 2019 May;94(S1):S3-S9. doi: 10.1002/ajh.25418. Epub 2019 Feb 18.
9
Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.阿维鲁单抗治疗复发性或难治性卵巢癌患者的疗效和安全性：JAVELIN 实体瘤试验的 1b 期结果。
JAMA Oncol. 2019 Mar 1;5(3):393-401. doi: 10.1001/jamaoncol.2018.6258.
10
Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028.派姆单抗治疗程序性死亡配体 1 阳性晚期卵巢癌患者：KEYNOTE-028 分析。
Gynecol Oncol. 2019 Feb;152(2):243-250. doi: 10.1016/j.ygyno.2018.11.017. Epub 2018 Dec 3.